Outsourcing in Clinical Trials USA – A Virtual Experience
The Clinical Trials market continues its growth because of increasing R&D expenditure in pharmaceutical and biopharmaceutical companies, globalisation of clinical…
All articles by Victoria Smith
Victoria Smith
-
-
Clinical Trial Supply 2020 – A virtual conference
2020 will see the return of the Clinical Trial Supply series to a new and innovative online platform for this…
-
FDA may be risk-averse to grant emergency use for a Covid-19 vaccine; political pressure and hazy EUA standards are factors
The FDA’s revocation of chloroquine and hydrochloroquine’s Emergency Use Authorization (EUA) after three months could mean the FDA may raise…
-
Gilead’s remdesivir to commence Phase I trials as inhaled therapy to target mild Covid-19 patients
Earlier this month, Gilead announced that it will commence Phase I clinical trials for inhaled remdesivir in healthy volunteers, with…
-
Dexamethasone, an unexpected drug, shows promise in treating Covid-19
At present, there are more than 2,200 clinical trials attempting to find a Covid-19 vaccine or therapy. The National Institute…
-
CanSino’s, J&J’s Covid-19 vaccines may be stifled by pre-existing antibodies while AstraZeneca’s, ReiThera’s may need booster
Notwithstanding its benefits over other vaccine technologies for Covid-19, adenovirus vector vaccines could be tripped up by pre-existing antibodies to…
-
The UK leads Covid-19 clinical investigations in Europe
As Europe has been significantly impacted by the Covid-19 pandemic, a huge amount of clinical research is focused on identifying…
-
Myovant’s Phase III relugolix trial’s cardiovascular event reduction trend inconclusive
At the beginning of the month, Myovant’s share price skyrocketed 55% after data from its Phase III HERO trial (NCT03085095)…
-
AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer
AstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell lung cancer (NSCLC), regardless of…
-
Long-term efficacy data shows MDMA is effective for treating PTSD
The Multidisciplinary Association for Psychedelic Studies (MAPS) is producing the first-in-class innovator drug midomafetamine (MDMA) as therapy for chronic and…